{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:37:47Z","timestamp":1791513467077,"version":"4.3.4"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Innovative Medicines Initiative 2 Joint Undertaking"},{"name":"European Union\u2019s Horizon"},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023699","name":"Health Data Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>More severe atopic dermatitis and psoriasis are associated with a higher cumulative impact on quality of life, multimorbidity and healthcare costs. Proactive, early intervention in those most at risk of severe disease may reduce this cumulative burden and modify the disease trajectory to limit progression. The lack of reliable biomarkers for this at-risk group represents a barrier to such a paradigm shift in practice. To expedite discovery and validation, the BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) consortium (a large-scale European, interdisciplinary research initiative) has curated clinical and molecular data across diverse study designs and sources including cross-sectional and cohort studies (small-scale studies through to large multicentre registries), clinical trials, electronic health records and large-scale population-based biobanks. We map all dataset disease severity instruments and measures to three key domains (symptoms, inflammatory activity and disease course), and describe important codependencies and relationships across variables and domains. We prioritize definitions for more severe disease with reference to international consensus, reference standards and\/or expert opinion. Key factors to consider when analysing datasets across these diverse study types include explicit early consideration of biomarker purpose and clinical context, candidate biomarkers associated with disease severity at a particular point in time and over time and how they are related, taking the stage of biomarker development into account when selecting disease severity measures for analyses, and validating biomarker associations with disease severity outcomes using both physician- and patient-reported measures and across domains. The outputs from this exercise will ensure coherence and focus across the BIOMAP consortium so that mechanistic insights and biomarkers are clinically relevant, patient-centric and more generalizable to current and future research efforts.<\/jats:p>","DOI":"10.1093\/bjd\/ljae080","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T23:28:03Z","timestamp":1709076483000},"page":"14-23","source":"Crossref","is-referenced-by-count":23,"title":["Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research: an\u00a0interdisciplinary perspective"],"prefix":"10.1093","volume":"191","author":[{"given":"Ravi","family":"Ramessur","sequence":"first","affiliation":[{"name":"St John\u2019s Institute of Dermatology"},{"name":"Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, Faculty of Life Sciences & Medicine, King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1805-6278","authenticated-orcid":false,"given":"Nick","family":"Dand","sequence":"additional","affiliation":[{"name":"Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, Faculty of Life Sciences & Medicine, King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin\u00e9ad M","family":"Langan","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Saklatvala","sequence":"additional","affiliation":[{"name":"Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, Faculty of Life Sciences & Medicine, King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Fritzsche","sequence":"additional","affiliation":[{"name":"Institute of History and Ethics in Medicine, TUM School of Medicine"},{"name":"Department of Science, Technology and Society, School of Social Sciences and Technology, Technical University of Munich , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzi","family":"Holland","sequence":"additional","affiliation":[{"name":"Eczema Outreach Support , Linlithgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd W M","family":"Arents","sequence":"additional","affiliation":[{"name":"Dutch Association for People with Atopic Dermatitis , Nijkerk , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McAteer","sequence":"additional","affiliation":[{"name":"The Psoriasis Association , Northampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Proctor","sequence":"additional","affiliation":[{"name":"National Eczema Society , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McMahon","sequence":"additional","affiliation":[{"name":"Irish Skin Foundation , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Greenwood","sequence":"additional","affiliation":[{"name":"Irish Skin Foundation , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena M","family":"Buyx","sequence":"additional","affiliation":[{"name":"Institute of History and Ethics in Medicine, TUM School of Medicine"},{"name":"Department of Science, Technology and Society, School of Social Sciences and Technology, Technical University of Munich , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Messer","sequence":"additional","affiliation":[{"name":"EURICE \u2013 European Research and Project Office GmbH , St. Ingbert , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Weiler","sequence":"additional","affiliation":[{"name":"EURICE \u2013 European Research and Project Office GmbH , St. Ingbert , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Hicks","sequence":"additional","affiliation":[{"name":"Immunology & Inflammation Research Therapeutic Area , Sanofi, Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hecht","sequence":"additional","affiliation":[{"name":"Public Private Partnerships, Sanofi Partnering , Frankfurt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology, University Hospital Schleswig-Holstein , Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matladi N","family":"Ndlovu","sequence":"additional","affiliation":[{"name":"UCB Pharma , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Chengliang","sequence":"additional","affiliation":[{"name":"Translational Medicine Department , UCB S.A., London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"H\u00fcbenthal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Quincke Research Center, University Hospital Schleswig-Holstein , Campus Kiel, Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bispebjerg Hospital , Copenhagen , Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Paternoster","sequence":"additional","affiliation":[{"name":"MRC Integrative Epidemiology Unit at the University of Bristol , Bristol , UK"},{"name":"Population Health Sciences, Bristol Medical School , Bristol, Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9680","authenticated-orcid":false,"given":"Lone","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark"},{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital \u2013 Herlev and Gentofte , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke M G J","family":"De Jong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Centre , Nijmegen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maritza A","family":"Middelkamp-Hup","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, Academic Medical Center, University of Amsterdam , Amsterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satveer K","family":"Mahil","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology"},{"name":"Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, Faculty of Life Sciences & Medicine, King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan N","family":"Barker","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology"},{"name":"Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, Faculty of Life Sciences & Medicine, King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4884-6286","authenticated-orcid":false,"given":"Carsten","family":"Flohr","sequence":"additional","affiliation":[{"name":"Unit for Paediatric and Population-Based Dermatology Research, St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara J","family":"Brown","sequence":"additional","affiliation":[{"name":"Centre for Genomic and Experimental Medicine, University of Edinburgh , Edinburgh , UK"},{"name":"Department of Dermatology , NHS Lothian, Edinburgh , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-1144","authenticated-orcid":false,"given":"Catherine H","family":"Smith","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"2024062015465511300_ljae080-B1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2024062015465511300_ljae080-B2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.19580","article-title":"The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990\u20132017","volume":"184","author":"Laughter","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/bjd.18622","article-title":"Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults","volume":"183","author":"Egeberg","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B4","doi-asserted-by":"crossref","first-page":"e049822","DOI":"10.1136\/bmjopen-2021-049822","article-title":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)","volume":"11","author":"Eyerich","year":"2021","journal-title":"BMJ Open"},{"key":"2024062015465511300_ljae080-B5","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis \u2013 a review on behalf of the International Eczema Council","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2024062015465511300_ljae080-B6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/bjd.20587","article-title":"The BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) glossary: developing a lingua franca to facilitate data harmonization and cross-cohort analyses","volume":"185","author":"Broderick","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B7","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0190-9622(03)02539-8","article-title":"Consensus conference on pediatric atopic dermatitis","volume":"49","author":"Eichenfield","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"2024062015465511300_ljae080-B8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bjd.20096","article-title":"Development of clinical diagnostic criteria for chronic plaque psoriasis: an international e-Delphi study","volume":"185","author":"Abo-Tabik","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.136.6.763","article-title":"Outcome measures of disease severity in atopic eczema","volume":"136","author":"Charman","year":"2000","journal-title":"Arch Dermatol"},{"key":"2024062015465511300_ljae080-B10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2133.1999.02963.x","article-title":"Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality","volume":"141","author":"Ashcroft","year":"1999","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jdv.18008","article-title":"Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics","volume":"36","author":"Bosma","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024062015465511300_ljae080-B12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjd.21627","article-title":"Biomarkers of disease progression in people with psoriasis: a scoping review","volume":"187","author":"Ramessur","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/all.15578","article-title":"Biomarkers associated with the development of comorbidities in patients with atopic dermatitis: a systematic review","volume":"78","author":"Broderick","year":"2023","journal-title":"Allergy"},{"key":"2024062015465511300_ljae080-B14","author":"Clinical Data Interchange Standards Consortium"},{"key":"2024062015465511300_ljae080-B15","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1111\/bjd.16543","article-title":"Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema\/dermatitis clinical trials (HOME initiative)","volume":"178","author":"Chalmers","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/bjd.15179","article-title":"Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures\u00a0for Eczema (HOME) statement","volume":"176","author":"Spuls","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","article-title":"Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council","volume":"82","author":"Strober","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024062015465511300_ljae080-B18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-019-00496-w","article-title":"Investigator and patient global assessment measures for psoriasis clinical trials: a systematic review on measurement properties from the International Dermatology Outcome Measures (IDEOM) Initiative","volume":"21","author":"Perez-Chada","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2024062015465511300_ljae080-B19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7861\/clinmedicine.14-2-178","article-title":"Psoriasis: guidance on assessment and referral","volume":"14","author":"Samarasekera","year":"2014","journal-title":"Clin Med (Lond"},{"key":"2024062015465511300_ljae080-B20","author":"Harmonising Outcome Measures for Eczema"},{"key":"2024062015465511300_ljae080-B21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","article-title":"Current severe psoriasis and the rule of tens","volume":"152","author":"Finlay","year":"2005","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/DER.0000000000000895","article-title":"The Eczema Area and Severity Index\u2013a practical guide","volume":"33","author":"Hanifin","year":"2022","journal-title":"Dermatitis"},{"key":"2024062015465511300_ljae080-B23","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/bjd.15641","article-title":"Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis","volume":"177","author":"Chopra","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B24","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/bjd.13662","article-title":"What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study","volume":"172","author":"Leshem","year":"2015","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B25","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41746-023-00914-8","article-title":"Systematic review of deep learning image analyses for the diagnosis and monitoring of skin disease","volume":"6","author":"Choy","year":"2023","journal-title":"NPJ Digital Med"},{"key":"2024062015465511300_ljae080-B27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.alit.2021.10.002","article-title":"Exacerbating factors and disease burden in patients with atopic dermatitis","volume":"71","author":"Murota","year":"2022","journal-title":"Allergol Int"},{"key":"2024062015465511300_ljae080-B28","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jaci.2017.09.044","article-title":"Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts","volume":"141","author":"Paternoster","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2024062015465511300_ljae080-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2021.0734","article-title":"Long-term outcomes and prognosis in new-onset psoriasis","volume":"157","author":"Svedbom","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2024062015465511300_ljae080-B30","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjd.18780","article-title":"Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP)","volume":"183","author":"Howells","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12895-019-0095-3","article-title":"Validation of the Atopic Dermatitis Control Tool (ADCT\u00a9) using a longitudinal survey of biologic-treated patients with atopic dermatitis","volume":"19","author":"Simpson","year":"2019","journal-title":"BMC Dermatol"},{"key":"2024062015465511300_ljae080-B32","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/ng.3985","article-title":"Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology","volume":"49","author":"Ferreira","year":"2017","journal-title":"Nat Genet"},{"issue":"Suppl. 2","key":"2024062015465511300_ljae080-B33","article-title":"Genetic epidemiology of psoriasis and psoriatic arthritis","volume":"64","author":"Rahman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2024062015465511300_ljae080-B34","doi-asserted-by":"crossref","first-page":"e12219","DOI":"10.1002\/clt2.12219","article-title":"The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis","volume":"13","author":"Spekhorst","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"2024062015465511300_ljae080-B35","doi-asserted-by":"crossref","first-page":"e1002739","DOI":"10.1371\/journal.pmed.1002739","article-title":"Evidence of a causal relationship between body mass index and psoriasis: a mendelian randomization study","volume":"16","author":"Budu-Aggrey","year":"2019","journal-title":"PLOS MED"},{"key":"2024062015465511300_ljae080-B36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34323-4","article-title":"Shared genetic risk factors and causal association between psoriasis and coronary artery disease","volume":"13","author":"Patrick","year":"2022","journal-title":"Nat Commun"},{"key":"2024062015465511300_ljae080-B37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12916-023-02948-x","article-title":"Common mental health disorders in adults with inflammatory skin conditions: nationwide population-based matched cohort studies in the UK","volume":"21","author":"Henderson","year":"2023","journal-title":"BMC Med"},{"key":"2024062015465511300_ljae080-B38","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/bjd\/ljac132","article-title":"Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis","volume":"188","author":"Adesanya","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","article-title":"The psychosocial burden of psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"2024062015465511300_ljae080-B40","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/bjd\/ljac132","article-title":"Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis","volume":"188","author":"Adesanya","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel\u00a0study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"2024062015465511300_ljae080-B42","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.det.2004.03.016","article-title":"Quality-of-life issues in psoriasis","volume":"22","author":"Mukhtar","year":"2004","journal-title":"Dermatol Clin"},{"key":"2024062015465511300_ljae080-B43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1525-1470.2005.22303.x","article-title":"The burden of atopic dermatitis: impact on the patient, family, and society","volume":"22","author":"Carroll","year":"2005","journal-title":"Pediatr Dermatol"},{"key":"2024062015465511300_ljae080-B44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000209234","article-title":"The psoriasis family index: preliminary results of validation of a quality of life instrument for family members of patients with psoriasis","volume":"219","author":"Eghlileb","year":"2009","journal-title":"Dermatology"},{"key":"2024062015465511300_ljae080-B45","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2133.2006.07617.x","article-title":"The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease","volume":"156","author":"Basra","year":"2007","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2133.1998.02034.x","article-title":"The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire","volume":"138","author":"Lawson","year":"1998","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11136-013-0457-y","article-title":"The development and validation of the Family Reported Outcome Measure (FROM-16)\u00a9 to assess the impact of disease on the partner or family member","volume":"23","author":"Golics","year":"2014","journal-title":"Qual Life Res"},{"key":"2024062015465511300_ljae080-B48","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1468-3083.2010.03705.x","article-title":"Psoriasis: is the impairment to a patient's life cumulative?","volume":"24","author":"Kimball","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024062015465511300_ljae080-B49","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1111\/jdv.17348","article-title":"Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases \u2013 a systematic review","volume":"35","author":"von St\u00fclpnagel","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024062015465511300_ljae080-B50","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/bjd.18296","article-title":"Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the U.K. and the U.S.A","volume":"182","author":"Andersen","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B51","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjd.18798","article-title":"A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis","volume":"183","author":"Villacorta","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B52","article-title":"Strategies to investigate and mitigate collider bias in genetic and Mendelian randomization studies of disease progression","author":"Mitchell","year":"2022","journal-title":"medRxiv"},{"key":"2024062015465511300_ljae080-B53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41584-018-0005-9","article-title":"Biomarkers as drug development tools: discovery, validation, qualification and use","volume":"14","author":"Kraus","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2024062015465511300_ljae080-B54","author":"FDA-NIH Biomarker Working Group"},{"key":"2024062015465511300_ljae080-B55","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3174\/ajnr.A2425","article-title":"Analysis by categorizing or dichotomizing continuous variables is inadvisable: an example from the natural history of unruptured aneurysms","volume":"32","author":"Naggara","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"key":"2024062015465511300_ljae080-B56","first-page":"233","volume-title":"Companion Encyclopedia of the History of Medicine","author":"Caplan","year":"1993"},{"key":"2024062015465511300_ljae080-B57","doi-asserted-by":"crossref","first-page":"116046","DOI":"10.1016\/j.socscimed.2023.116046","article-title":"A severely fragmented concept: uncovering citizens\u2019 subjective accounts of severity of illness","volume":"330","author":"Stenmarck","year":"2023","journal-title":"Soc Sci Med"},{"key":"2024062015465511300_ljae080-B58","author":"V\u00e4yrynen"},{"key":"2024062015465511300_ljae080-B59","author":"Crisp"},{"key":"2024062015465511300_ljae080-B60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12910-023-00903-2","article-title":"Severity as a moral qualifier of malady","volume":"24","author":"Solberg","year":"2023","journal-title":"BMC Medical Ethics"},{"key":"2024062015465511300_ljae080-B61","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/jdv.18128","article-title":"Mapping ethical and social aspects of biomarker research and its application in atopic dermatitis and psoriasis: a systematic review of reason","volume":"36","author":"Fritzsche","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024062015465511300_ljae080-B62","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780198237907.001.0001","volume-title":"Epistemic Injustice: Power and the Ethics of Knowing","author":"Fricker","year":"2007"},{"key":"2024062015465511300_ljae080-B63","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.healthpol.2009.08.005","article-title":"Severity of illness and priority setting in healthcare: a review of the literature","volume":"93","author":"Shah","year":"2009","journal-title":"Health Policy"},{"key":"2024062015465511300_ljae080-B64","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/medethics-2018-105058","article-title":"The significance of \u2018severity\u2019","volume":"45","author":"Hausman","year":"2019","journal-title":"J Med Ethics"},{"key":"2024062015465511300_ljae080-B65","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.healthpol.2014.02.009","article-title":"Concerns for severity in priority setting in health care: a review of trade-off data in preference studies and implications for societal willingness to pay for a QALY","volume":"116","author":"Nord","year":"2014","journal-title":"Health Policy"},{"key":"2024062015465511300_ljae080-B66","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10728-019-00371-z","article-title":"Severity as a priority setting criterion: setting a challenging research agenda","volume":"28","author":"Barra","year":"2020","journal-title":"Health Care Anal"},{"key":"2024062015465511300_ljae080-B67","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1203475420923644","article-title":"Common atopic dermatitis rating scales: a practical approach and brief review [Formula: see text]","volume":"24","author":"Yang","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"2024062015465511300_ljae080-B68","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bjd.12590","article-title":"Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods","volume":"169","author":"Charman","year":"2013","journal-title":"Br J Dermatol"},{"key":"2024062015465511300_ljae080-B69","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","article-title":"The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective","volume":"140","author":"Charman","year":"2004","journal-title":"Arch Dermatol"},{"key":"2024062015465511300_ljae080-B70","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jaci.2020.12.001","article-title":"Atopic eczema in adulthood and mortality: UK population-based cohort study, 1998-2016","volume":"147","author":"Silverwood","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2024062015465511300_ljae080-B71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41687-017-0004-7","article-title":"The content validity of the PSS in patients with plaque psoriasis","volume":"1","author":"Rentz","year":"2017","journal-title":"J Patient Rep Outcomes"},{"key":"2024062015465511300_ljae080-B72","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jaci.2022.03.017","article-title":"The HOME core outcome set for clinical trials of atopic dermatitis","volume":"149","author":"Williams","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae080\/57094654\/ljae080.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/1\/14\/58289229\/ljae080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/1\/14\/58289229\/ljae080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T15:47:42Z","timestamp":1718898462000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/1\/14\/7616107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,29]]},"published-print":{"date-parts":[[2024,6,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae080","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,2,29]]}}}